Search
Galmed Pharmaceuticals Ltd
GLMDAdd to Watchlist
0.570USD
-0.079-12.34%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
3.75MMarket Cap
LossP/E TTM
More Details of Galmed Pharmaceuticals Ltd Company
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd Info
Ticker SymbolGLMD
Company nameGalmed Pharmaceuticals Ltd
IPO dateMar 13, 2014
CEOBaharaff (Allen)
Number of employees3
Security typeOrdinary Share
Fiscal year-endMar 13
Address16 Tiomkin Street
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code6578317
Phone97236938448
Websitehttps://www.galmedpharma.com
Ticker SymbolGLMD
IPO dateMar 13, 2014
CEOBaharaff (Allen)
Company Executives of Galmed Pharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
13.96K
+77.62%
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
127.23K
+70.97%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
27.95K
+77.52%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
27.95K
+77.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
27.92K
+77.61%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
14.23K
+76.14%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
14.00K
+77.69%
FAQs
Who are the top five shareholders of Galmed Pharmaceuticals Ltd?
The top five shareholders of Galmed Pharmaceuticals Ltd are: Mr. Allen Baharaff
How many institutions hold shares of Galmed Pharmaceuticals Ltd (GLMD)?
As of 2026Q1, 30 institutions hold shares of Galmed Pharmaceuticals Ltd, with a combined market value of approximately 224.38K, accounting for 3.40% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 75169.00.